Value Drug Co. v. Takeda Pharm., U.S.A.

Full title: VALUE DRUG COMPANY v. TAKEDA PHARMACEUTICALS, U.S.A., INC., et al.

Court: United States District Court, E.D. Pennsylvania

Date published: Apr 4, 2022

Civil Action 21-3500 (E.D. Pa. Apr. 4, 2022)

Opinion

Civil Action 21-3500

04-04-2022

VALUE DRUG COMPANY v. TAKEDA PHARMACEUTICALS, U.S.A., INC., et al.

KEARNEY, J.

ORDER

KEARNEY, J.

AND NOW, this 4^th day of April 2022, consistent with our March 15, 2022 Order (ECF Doc. No. 198), following independent review of Special Master Judge Vanaskie's Report and Recommendation (ECF Doc. No. 210) addressing Plaintiffs Motion to compel discovery (ECF Doc. No. 182), with no timely objection, and finding good cause, it is ORDERED:

1. We ADOPT Judge Vanaskie's Report and Recommendation (ECF Doc. No. 210);

2. We GRANT Plaintiffs Motion to compel discovery (ECF Doc. No. 182) in part, requiring, on or before April 8, 2022:

a. Takeda shall complete the searches required in paragraph 17(a) and 17(b) of Plaintiffs search request beginning in 2011 through the year 2021;

b. Par shall produce the documents responsive to request No. 16 of the Plaintiffs first Requests for documents;

c. The producing party shall provide a fulsome privilege log of all information withheld based on a specifically defined privilege; and,

3. Plaintiff s Motion (ECF Doc. No. 182) is otherwise DENIED.